Journal
RESPIRATORY MEDICINE CASE REPORTS
Volume 25, Issue -, Pages 261-263Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.rmcr.2018.10.004
Keywords
Repeated genetic testing; Drug resistance; EGFR-T790M; SCLC transformation; Liquid biopsy
Categories
Ask authors/readers for more resources
NSCLC patients with EGFR mutations respond to EGFR-TKIs; however, the management of refractory tumors to EGFR-TKIs remains unclear. We demonstrated that repeated genetic testing might be useful for detecting resistance mechanisms as well as for decision-making in EGFR mutated NSCLC patients, following the emergence of resistance to the initial EGFR-TKIs. A 69-year-old man was diagnosed with lung adenocarcinoma with an EGFR exon 19 deletion. After tumor regrowth treated with erlotinib and chemotherapy, he was diagnosed with an SCLC transformation and administered chemotherapy to treat the SCLC. After the resistance of chemotherapy, the EGFR-T790M mutation by liquid biopsy was detected and treated him with osimertinib, which resulted in a clinical response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available